On October 7, 2021, ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that ALX has acquired ScalmiBio. Wilson Sonsini Goodrich & Rosati represented ALX Oncology in the transaction.

ALX Oncology will further expand its pipeline  by developing new anti-cancer drug candidates based on ScalmiBio’s platform; these new molecules will be designed to address unmet cancer patient needs as stand-alone therapeutics and in combination with ALX Oncology’s lead product candidate, evorpacept, a next-generation CD47 blocker designed to leverage the immune activation of broadly used anti-cancer agents through combination strategies. ALX Oncology has also acquired ScalmiBio’s proprietary cytotoxic payloads for the development of ADCs.

The Wilson Sonsini team that advised ALX Oncology on the transaction includes Michael Coke, Scott McCall, Myra Sutanto Shen, Jackie Tokuda, Rebecca Stuart, Tracy Sevush, Sara Dunton, Jason Chan, Abhinaya Prithivi, and Kexi Wang.

For more information, please see the press release.